BACKGROUND: The impact of highly active antiretroviral therapy (HAART) on the natural history of human papillomavirus (HPV) remains uncertain following conflicting reports. Prior studies, however, did not consider patients' adherence to their regimens or HAART effectiveness (viral suppression). METHODS: Human immunodeficiency virus (HIV)-positive women (N = 286) who initiated HAART during follow-up in a prospective cohort were assessed semiannually for HPV infection (by polymerase chain reaction) and squamous intraepithelial lesions (SILs). Adherence was defined as use of HAART as prescribed > or = 95% of the time, and effective HAART was defined as suppression of HIV replication. The prevalence, incident detection, and clearance of HPV infection and/or SILs before versus after HAART initiation were compared (using women as their own comparison group). RESULTS: HAART initiation among adherent women was associated with a significant reduction in prevalence (odds ratio, 0.60 [95% confidence interval {CI}, 0.44-0.81]; P = .001), incident detection of oncogenic HPV infection (hazard ratio [HR], 0.49 [95% CI, 0.30-0.82]; P = .006), and decreased prevalence and more rapid clearance of oncogenic HPV-positive SILs (HR, 2.35 [95% CI, 1.07-5.18]; P = .03). Effects were smaller among nonadherent women. The associations of HPV infection and/or SILs with HAART effectiveness were fairly similar to those with HAART adherence. CONCLUSION: Effective and adherent HAART use is associated with a significantly reduced burden of HPV infection and SILs; this may help explain why rates of cervical cancer have not increased during the HAART era, despite greater longevity.
BACKGROUND: The impact of highly active antiretroviral therapy (HAART) on the natural history of human papillomavirus (HPV) remains uncertain following conflicting reports. Prior studies, however, did not consider patients' adherence to their regimens or HAART effectiveness (viral suppression). METHODS:Human immunodeficiency virus (HIV)-positive women (N = 286) who initiated HAART during follow-up in a prospective cohort were assessed semiannually for HPV infection (by polymerase chain reaction) and squamous intraepithelial lesions (SILs). Adherence was defined as use of HAART as prescribed > or = 95% of the time, and effective HAART was defined as suppression of HIV replication. The prevalence, incident detection, and clearance of HPV infection and/or SILs before versus after HAART initiation were compared (using women as their own comparison group). RESULTS: HAART initiation among adherent women was associated with a significant reduction in prevalence (odds ratio, 0.60 [95% confidence interval {CI}, 0.44-0.81]; P = .001), incident detection of oncogenic HPV infection (hazard ratio [HR], 0.49 [95% CI, 0.30-0.82]; P = .006), and decreased prevalence and more rapid clearance of oncogenic HPV-positive SILs (HR, 2.35 [95% CI, 1.07-5.18]; P = .03). Effects were smaller among nonadherent women. The associations of HPV infection and/or SILs with HAART effectiveness were fairly similar to those with HAART adherence. CONCLUSION: Effective and adherent HAART use is associated with a significantly reduced burden of HPV infection and SILs; this may help explain why rates of cervical cancer have not increased during the HAART era, despite greater longevity.
Authors: Xiaonan Xue; Stephen J Gange; Ye Zhong; Robert D Burk; Howard Minkoff; L Stewart Massad; D Heather Watts; Mark H Kuniholm; Kathryn Anastos; Alexandra M Levine; Melissa Fazzari; Gypsyamber D'Souza; Michael Plankey; Joel M Palefsky; Howard D Strickler Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01 Impact factor: 4.254
Authors: Benigno Rodríguez; Ajay K Sethi; Vinay K Cheruvu; Wilma Mackay; Ronald J Bosch; Mari Kitahata; Stephen L Boswell; W Christopher Mathews; David R Bangsberg; Jeffrey Martin; Christopher C Whalen; Scott Sieg; Suhrida Yadavalli; Steven G Deeks; Michael M Lederman Journal: JAMA Date: 2006-09-27 Impact factor: 56.272
Authors: Farzana Kapadia; David Vlahov; Yingfeng Wu; Mardge H Cohen; Ruth M Greenblatt; Andrea A Howard; Judith A Cook; Lakshmi Goparaju; Elizabeth Golub; Jean Richardson; Tracey E Wilson Journal: Am J Drug Alcohol Abuse Date: 2008 Impact factor: 3.829
Authors: Roberto Ortiz; Edwin Dejesus; Homayoon Khanlou; Evgeniy Voronin; Jan van Lunzen; Jaime Andrade-Villanueva; Jan Fourie; Sandra De Meyer; Martine De Pauw; Eric Lefebvre; Tony Vangeneugden; Sabrina Spinosa-Guzman Journal: AIDS Date: 2008-07-31 Impact factor: 4.177
Authors: Pangaja Paramsothy; Denise J Jamieson; Charles M Heilig; Paula C Schuman; Robert S Klein; Keerti V Shah; Anne M Rompalo; Susan Cu-Uvin; Ann Duerr Journal: Obstet Gynecol Date: 2009-01 Impact factor: 7.661
Authors: Howard Minkoff; Ye Zhong; Howard D Strickler; D Heather Watts; Joel M Palefsky; Alexandra M Levine; Gypsyamber D'Souza; Andrea A Howard; Michael Plankey; L Stewart Massad; Robert Burk Journal: Infect Dis Obstet Gynecol Date: 2008
Authors: Cecile D Lahiri; Katherine B Dugan; Xianhong Xie; Laura Reimers; Robert D Burk; Kathryn Anastos; Leslie Stewart Massad; Isam-Eldin Eltoum; Xiaonan Xue; Gypsyamber DʼSouza; Lisa Flowers; Joel M Palefsky; Lisa Rahangdale; Howard D Strickler; Ighovwerha Ofotokun Journal: J Acquir Immune Defic Syndr Date: 2015-10-01 Impact factor: 3.731
Authors: L Stewart Massad; Xianhong Xie; Gypsyamber D'Souza; Teresa M Darragh; Howard Minkoff; Rodney Wright; Christine Colie; Lorraine Sanchez-Keeland; Howard D Strickler Journal: Am J Obstet Gynecol Date: 2014-12-10 Impact factor: 8.661
Authors: Alison G Abraham; Gypsyamber D'Souza; Yuezhou Jing; Stephen J Gange; Timothy R Sterling; Michael J Silverberg; Michael S Saag; Sean B Rourke; Anita Rachlis; Sonia Napravnik; Richard D Moore; Marina B Klein; Mari M Kitahata; Gregory D Kirk; Robert S Hogg; Nancy A Hessol; James J Goedert; M John Gill; Kelly A Gebo; Joseph J Eron; Eric A Engels; Robert Dubrow; Heidi M Crane; John T Brooks; Ronald J Bosch; Howard D Strickler Journal: J Acquir Immune Defic Syndr Date: 2013-04-01 Impact factor: 3.731
Authors: Elizabeth Y Chiao; Christine M Hartman; Hashem B El-Serag; Thomas P Giordano Journal: J Acquir Immune Defic Syndr Date: 2013-08-15 Impact factor: 3.731